1129541-03-2

Basic information

• Product Name: 4-(3-fluoro-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)phenyl)Morpholine
• Synonyms: 4-(3-fluoro-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)phenyl)Morpholine;3-Fluoro-5-(morpholino)phenylboronic acid pinacol ester
• CAS NO: 1129541-03-2
• Molecular Formula: C₁₆H₂₃BFNO₃
• Molecular Weight: 307.1681232
• Mol File: 1129541-03-2.mol

Chemical Properties

• Boiling Point: 440.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.14±0.1 g/cm3(Predicted)
• PKA: 3.92±0.40(Predicted)
• CAS DataBase Reference: 4-(3-fluoro-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)phenyl)Morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-fluoro-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)phenyl)Morpholine(1129541-03-2)
• EPA Substance Registry System: 4-(3-fluoro-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)phenyl)Morpholine(1129541-03-2)

Safety Data

• Hazardous Substances Data: 1129541-03-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)Morpholine is used as a reactant in the preparation of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors. These inhibitors are important in the development of drugs targeting the JNK pathway, which plays a crucial role in various cellular processes, including inflammation, cell growth, and apoptosis. By inhibiting JNK, these compounds may have therapeutic potential in treating a range of diseases, such as neurodegenerative disorders, inflammatory conditions, and cancer.
In the synthesis of JNK inhibitors, 4-(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)Morpholine serves as a key building block, providing the necessary structural elements for the formation of the final product. Its reactivity and compatibility with various synthetic methods make it a versatile component in the development of new and effective JNK inhibitors.
Overall, 4-(3-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)Morpholine is a significant compound in the pharmaceutical industry, particularly in the synthesis of JNK inhibitors. Its unique structure and reactivity contribute to the development of potential therapeutic agents that target important cellular pathways and may offer new treatment options for various diseases.

Upstream product

• 1129541-62-3 4-(3-bromo-5-fluorophenyl)morpholine 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1129541-05-4 4-(3-(2-chloropyrimidin-4-yl)-5-fluorophenyl)morpholine 

Relevant articles and documents

Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors

Given the significant body of data supporting an essential role for c-jun-N-terminal kinase (JNK) in neurodegenerative disorders, we set out to develop highly selective JNK inhibitors with good cell potency and good brain penetration properties. The structure-activity relationships (SAR) around a series of aminopyrimidines were evaluated utilizing biochemical and cell-based assays to measure JNK inhibition and brain penetration in mice. Microsomal stability in three species, P450 inhibition, inhibition of generation of reactive oxygen species (ROS), and pharmacokinetics in rats were also measured. Compounds 9g, 9i, 9j, and 9l had greater than 135-fold selectivity over p38, and cell-based IC50 values 50 = 0.8 nM for inhibition of ROS and had good pharmacokinetic properties in rats along with a brain-to-plasma ratio of 0.75. These results suggest that biaryl substituted aminopyrimidines represented by compound 9l may serve as the first small molecule inhibitors to test efficacy of JNK inhibitors in neurodegenerative disorders. 2009 American Chemical Society.

SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS

The present invention provides novel substituted pyrimidinyl-amines that are useful as inhibitors of protein kinases, especially c-Jun N-terminal kinases (JNK) and pharmaceutical compositions thereof and methods of using the same for treating conditions responsive to the inhibition of the JNK pathway.